Deerfield Management Company L.P. Series C Acquires 3,790,518 Shares of Indivior PLC (NASDAQ:INDV)

Deerfield Management Company L.P. Series C grew its holdings in shares of Indivior PLC (NASDAQ:INDV) by 74.4% during the fourth quarter, Holdings Channel reports. The firm owned 8,883,160 shares of the company’s stock after purchasing an additional 3,790,518 shares during the period. Indivior accounts for about 2.1% of Deerfield Management Company L.P. Series C’s portfolio, making the stock its 14th largest position. Deerfield Management Company L.P. Series C owned about 0.06% of Indivior worth $110,418,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Rathbones Group PLC lifted its position in shares of Indivior by 11.6% in the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company’s stock worth $183,000 after buying an additional 1,483 shares during the last quarter. Stifel Financial Corp raised its position in shares of Indivior by 24.0% in the fourth quarter. Stifel Financial Corp now owns 12,675 shares of the company’s stock valued at $158,000 after purchasing an additional 2,450 shares during the period. PDT Partners LLC lifted its stake in shares of Indivior by 4.7% in the fourth quarter. PDT Partners LLC now owns 57,520 shares of the company’s stock worth $715,000 after buying an additional 2,596 shares during the last quarter. Clark Estates Inc. NY boosted its holdings in shares of Indivior by 1.3% during the 4th quarter. Clark Estates Inc. NY now owns 257,400 shares of the company’s stock worth $3,199,000 after buying an additional 3,300 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Indivior in the 4th quarter valued at $56,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Analyst Ratings Changes

INDV has been the subject of a number of research analyst reports. Rodman & Renshaw started coverage on shares of Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 target price for the company. RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, Piper Sandler dropped their price objective on Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th.

Indivior Price Performance

Shares of Indivior stock opened at $11.50 on Thursday. The firm has a 50 day simple moving average of $9.92 and a 200 day simple moving average of $10.50. The firm has a market cap of $1.58 billion, a P/E ratio of -32.84 and a beta of 0.98. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $18.59.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.19. The firm had revenue of $266.00 million for the quarter, compared to analysts’ expectations of $240.13 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. On average, sell-side analysts expect that Indivior PLC will post 1.22 EPS for the current year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.